Orchestra BioMed Holdings, Inc.: 10-Q filed 2022-05-13

Name: Orchestra BioMed Holdings, Inc.: 10-Q filed 2022-05-13
Creator: Orchestra BioMed Holdings, Inc.

What Orchestra BioMed Holdings, Inc. reported in its quarterly report filed 2022-05-13 (fiscal Q1 2022): 19 published measures, 42 facts as tagged in accession 0001213900-22-026427.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-05-13
Fiscal period: fiscal Q1 2022
Accession: 0001213900-22-026427 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Orchestra BioMed Holdings, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-03-31	161,526,884	USD
At 2021-12-31	161,823,574	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-03-31	5,906,538	USD
At 2021-12-31	5,765,539	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-03-31	-4,379,654	USD
At 2021-12-31	-3,941,965	USD
At 2021-03-31	-3,671,214	USD
At 2020-12-31	-3,563,212	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2022-03-31	1,418,880	USD
At 2021-12-31	1,754,460	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-437,689	USD	90
2021-01-01 to 2021-03-31	-108,002	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-335,580	USD	90
2021-01-01 to 2021-03-31	-76,374	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-03-31	-4,380,099	USD
At 2021-12-31	-3,942,410	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	20,450,000	shares	90
2021-01-01 to 2021-03-31	20,450,000	shares	90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-0.02	USD/shares	90
2021-01-01 to 2021-03-31	-0.01	USD/shares	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-451,954	USD	90
2021-01-01 to 2021-03-31	-111,948	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-03-31	1,490,172	USD
At 2021-12-31	1,801,127	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-03-31	306,538	USD
At 2021-12-31	165,539	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2022-03-31	103,607	USD
At 2021-12-31	1,388	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-03-31	4,450,000	shares
At 2021-12-31	4,450,000	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2022-03-31	1,418,880	USD
At 2021-12-31	1,754,460	USD
At 2021-03-31	1,950,448	USD
At 2020-12-31	2,026,822	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2022-03-31	202,931	USD
At 2021-12-31	14,151	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-437,689	USD	90
2021-01-01 to 2021-03-31	-108,002	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	421,954	USD	90
2021-01-01 to 2021-03-31	81,948	USD	90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	102,219	USD	90
2021-01-01 to 2021-03-31	20,750	USD	90

Inspect the source

Entity: Orchestra BioMed Holdings, Inc. / CIK 0001814114
Captured: 2026-09-21T17:33:55.958Z
SEC response SHA-256: f490c393d405fb139d3488fa9c027ee1423073551fb45f7969fec942006123e2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001814114.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))